{"id":"W4386152079","doi":"10.1002/cncr.34987","title":"Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial","year":2023,"lang":"en","type":"article","venue":"Cancer","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Seagen; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Pharmacyclics; Genentech; Legend Biotech; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Multiple myeloma; Refractory (planetary science); Adverse effect; Clinical endpoint; Anemia; Gastroenterology; Quality of life (healthcare); Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001396068,0.0001469082,0.0004028997,0.0003631774,0.00005956663,0.000008613955,0.0001234029,0.00006971059,0.0002392188],"category_scores_gemma":[0.0001938438,0.00008738416,0.0001688078,0.001690398,0.00009218366,0.00004781426,0.00006741902,0.000188415,0.00002028915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003301794,"about_ca_system_score_gemma":0.000184508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006183491,"about_ca_topic_score_gemma":0.001424197,"domain_scores_codex":[0.9983875,0.00008518219,0.0002834183,0.0002856891,0.0006136952,0.000344478],"domain_scores_gemma":[0.9991101,0.0001407952,0.0001212305,0.0003960668,0.00011512,0.000116678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02254727,0.0008149775,0.9630261,0.00003362539,0.00096059,0.00003723004,0.0001943013,0.0001305467,0.0002996988,0.000002127062,0.0004383374,0.01151522],"study_design_scores_gemma":[0.06189574,0.0006796567,0.9346823,0.000104499,0.0005127969,2.762371e-7,0.00004441051,0.0004802072,0.0008074551,0.000001769241,0.0007087938,0.00008213046],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982076,0.0001032843,0.00000249719,0.0001692497,0.0001595026,0.0008964664,0.000150056,0.00002689703,0.0002844219],"genre_scores_gemma":[0.998355,0.00003790052,0.00003352353,0.0000465982,0.00006002025,0.0001383639,0.0001674463,0.00002081176,0.001140308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03934846,"threshold_uncertainty_score":0.3563422,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04513348790059476,"score_gpt":0.3060874820950584,"score_spread":0.2609539941944636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}